NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.

Also called NCT02722473

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose diagnostic
Phase
Phase 3
Enrolled
  • 106 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02722473
Other papers using this trial's data
  • NSE as a predictor of death or poor neurological outcome after non-shockable cardiac arrest due to any cause: Ancillary study of HYPERION trial data Resuscitation, 2021-01 DOI, PubMed 33301887

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02722473. Randomized; single masking; primary purpose diagnostic. Start 2016-03 (registry gives no type); primary completion 2018-01-14 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.
Acronym
NSE-HYPERION
Condition
Hypothermia
Condition
Critical Care
Intervention (Biological)
NSE dosage "hypothermia arm"
Intervention (Biological)
NSE dosage "normothermia arm"
Lead sponsor
Centre Hospitalier Departemental Vendee (class: other)

Record details

Record id
cardio:ct-nct02722473
Content hash
d2ebeef628639eb18aceb704e518234c6505683bde2ad3c7c172aadd6a408c76